Knockdown of the SS18-SSX fusion protein in synovial sarcoma displayed similar anti-proliferative effects compared to treatment with the BRD9 chemical inhibitor dBRD9, but further investigation also uncovered that full degradation of BRD9 by this inhibitor did not affect SS18-SSX-mediated gene activation [107]. Here, BRD9 is linked to synovial sarcoma.